ClinVar Miner

Submissions for variant NM_000257.4(MYH7):c.4126G>A (p.Glu1376Lys)

dbSNP: rs730880791
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000158635 SCV000208570 likely pathogenic not provided 2014-04-20 criteria provided, single submitter clinical testing p.Glu1376Lys (GAG>AAG): c.4126 G>A in exon 30 of the MYH7 gene (NM_000257.2). A E1376K variant that is likely pathogenic was identified in the MYH7 gene. This variant has not been published as a mutation or as a benign polymorphism to our knowledge. The E1376K variant was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The E1376K variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. This substitution occurs at a position that is conserved across species. Consequently, in silico analysis predicts this variant may be damaging to the protein structure/function. Furthermore, missense mutations in nearby residues (T1377M, A1379T, R1382Q, R1382W) have been reported in association with hypertrophic cardiomyopathy, supporting the functional importance of this region of the protein. Therefore, this variant is a strong candidate for a pathogenic mutation. However, the possibility that it is a benign variant cannot be excluded. The variant is found in CARDIOMYOPATHY panel(s).
Ambry Genetics RCV002326900 SCV002632686 uncertain significance Cardiovascular phenotype 2020-12-28 criteria provided, single submitter clinical testing The p.E1376K variant (also known as c.4126G>A), located in coding exon 28 of the MYH7 gene, results from a G to A substitution at nucleotide position 4126. The glutamic acid at codon 1376 is replaced by lysine, an amino acid with similar properties. This alteration was reported in a dilated cardiomyopathy (DCM) (Mazzarotto F et al. Circulation, 2020 02;141:387-398). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.